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Abstract
Substance Use Disorder (SUD) is a major public health concern affecting an estimated 22.5
million individuals in the United States. The primary aim of this study was to characterize
psychological pain in a cohort of patients participating in outpatient treatment for SUD. A
secondary aim was to determine the relationships between pre-treatment assessments of
psychological pain, depression, anxiety and hopelessness with treatment retention time and
completion rates. Data was analyzed from 289 patients enrolled in an outpatient community
drug treatment clinic in Southern California, U.S. A previously determined threshold score
on the Mee-Bunney Psychological Pain Assessment Scale (MBP) was utilized to group
patients into high and low-moderate scoring subgroups. The higher pain group scored
higher on measures of anxiety, hopelessness and depression compared to those in the low-
moderate pain group. Additionally, patients scoring in the higher psychological pain group
exhibited reduced retention times in treatment and more than two-fold increased odds of
dropout relative to patients with lower pre-treatment levels of psychological pain. Among all
assessments, the correlation between psychological pain and treatment retention time was
strongest. To our knowledge, this is the first study to demonstrate that psychological pain is
an important construct which correlates with relevant clinical outcomes in SUD. Further-
more, pre-treatment screening for psychological pain may help target higher-risk patients
for clinical interventions aimed at improving treatment retention and completion rates.
Introduction
Substance Use Disorder (SUD) is a major public health concern affecting an estimated 22.5
million individuals in the United States [1]. In 2017, 70,237 deaths were attributed to drug
overdoses—a significant increase of 9.6% over the past year [2]. Nationally, substance-related
addiction incurs a financial burden exceeding $400 billion per year including expenses related
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to lost work productivity, healthcare and drug-related crime [3]. There are 14,500 drug treat-
ment centers in the US but only a relatively small number of individuals (11%) enter treatment
despite the fact that many programs are supported by local, State and Federal government
funding [4]. Drug treatment programs continue to strive for improving program outcomes,
however, data shows that they are maximally effective when patients remain in treatment
(length of stay-LOS) for an average of 90 days or more [5, 6]. Program completion is associated
with better health, fewer readmissions, less criminal activity [7] and lower mortality rates [8].
Poor retention rates (inadequate LOS) and failure to complete (Dropout) pose major clinical
challenges [9] to successful substance treatment. Of those SUD individuals entering a program,
17–67% complete treatment depending on the substance of choice and whether therapy is
offered as in- or outpatient [7]. Efforts to identify factors predictive of treatment non-comple-
tion have shown that demographics alone are relatively poor indicators while inadequate
length of stay (LOS) negatively impacts treatment outcomes. [7, 10].
Psychological pain has emerged as an important clinical psychometric construct. Attempts
to measure and characterize psychological pain began with early investigations into its impact
on suicidality and more recently in populations suffering from Major Depression [11, 12],[13–
21]. It has been characterized by investigators as an ‘Emotionally-based, extremely aversive
feeling’ and ‘A response to noxious psychological stimuli, analogous to physical pain that. . .
may operate on a continuum from mild to severe.’ Other groups have defined psychological
pain as ‘The hurt, anguish, soreness, aching, psychological pain in the psyche.’ Still others as ‘A
lasting, unpleasant and unsustainable feeling characterized by a perception of inability or defi-
ciency of the self. . .’ [22–24]. Investigators have variously referred to this form of pain as men-
tal pain, emotional pain, social pain or psychache. The construct models reveal two broad
categories of conceptual framework: 1) a more generalized negative internal response to real
or perceived deficiencies of self and 2) a narrower, negative emotionally-based aversive
response to internal and external stressors most analogous to physical nociception. The dispa-
rate state of construct understanding and lack of cohesive definition reveals a field that is
maturing but requires more research to develop a truly unified definition and discern its rela-
tionship to other broader theories of negative emotional responsiveness such as Negative
Affectivity (37) and internalizing psychopathology. We propose that the narrower concept of
psychological pain as an aversive signal analogous to physical pain and similarly generative of
profoundly negative emotional experiences, allows for consideration of its relationship to sui-
cidality and possibly SUD as a means to escape, moderate or otherwise control psychological
pain. Further data are required to mature the construct and elucidate its relationship to related
concepts of NA and internalizing psychopathology.
There is very little data characterizing psychological pain in SUD. Guimaraes et al. assessed
psychological pain in a population undergoing treatment for SUD using a translated (English
to Portuguese) abbreviated version (24 items) of the Orbach & Mikulincer Mental Pain Scale
(OMMP), finding a small to moderate positive correlation between mental pain and the sever-
ity of addiction [25]. A Norwegian study addressing ‘mental distress’ and variables related to
dropout included 454 patients from five inpatient SUD treatment centers using a brief version
(10-item) of the Hopkins Symptom Checklist (HSCL). The HSCL assesses obsessive-compul-
sivity, somatization, anxiety and depression. A high score on the HSCL, which the investiga-
tors interpreted as ‘mental distress’, was associated with treatment dropout [26]. The HSCL,
however, does not specifically define or claim to assess psychological pain. Some have specu-
lated that use of addictive substances to suppress negative emotions so that the control of men-
tal pain (e.g., drug seeking induced by acute stress) may be the objective of substance use
behaviors, rather than the pleasure-seeking associated with substance use [27]. Conclusive evi-
dence characterizing psychological pain in SUD and documenting its clinical implications is
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largely lacking. In its absence, a convergence of evidence supporting a link through shared
clinical comorbidities of depression and suicidality as well as data from at least one study,
encourage efforts to further our understanding. Previously, we documented that patients
experiencing a Major Depressive Episode reported elevated psychological pain relative to
healthy controls. Psychological pain was significantly correlated with both the intensity of
depressive symptoms as well as suicidal ideation(10). Further, 87% of subjects reporting the
highest category of psychological pain (MBP� 32) also met DSM-IV criteria for a current
Major Depressive Episode. A follow-up study performed in a separate population of acutely
suicidal U.S. Veterans, found psychological pain to be correlated with depression and suicidal-
ity scores (11). Moreover, those patients with future suicidal behavior observed over an
18-month observation period all had high scores of psychological pain. These findings are con-
sistent with previous reports demonstrating a correlation between psychological pain, depres-
sion and suicidality (11–13), albeit with fewer efforts focused on specific mood disorder
populations (17). Depression and elevated suicidality, both shown to be correlated with psy-
chological pain, are also commonly seen in patients with SUD (35,36). The phenomenological
and clinical overlap between depression, suicidality, psychological pain and SUD suggests that
psychological pain is elevated in SUD and that higher levels of pain could impede treatment.
Although comprehensive characterizations of psychological pain and potential impacts on
SUD treatment are lacking, a growing convergence of circumstantial, clinical and theoretical
evidence supports further investigation of these questions and is the impetus for the current
study.
This study was undertaken to characterize psychological pain in a population undergoing
treatment for SUD. We hypothesized that psychological pain scores would be correlated with
assessments of depression and anxiety as we observed in previously studied depressed and sui-
cidal clinical populations [11, 12]. The MBP is a brief 10-item self-report instrument developed
for use in a variety of clinical settings. It defines the construct of psychological pain for patients
to use when answering the items as ‘Intense psychological pain is a feeling which is experi-
enced as unbearable torment. It can be experienced during a psychiatric disorder or a tragic
loss such as the death of a child. . . circle the number that best describes how often you experi-
ence severe psychological pain.’ Items are rated on a 5-point Likert Scale and include content
examining current and past (within 3 months) psychological pain in terms of frequency, inten-
sity levels, and perceived tolerance (e.g., how much psychological pain can you tolerate before
it becomes unbearable?). Administering the scale to a population diagnosed with current
Major Depressive Episodes (MDE), we found increased levels of psychological pain in
depressed patients compared with healthy controls [12]. Secondary findings included signifi-
cant correlations between psychological pain, depression, hopelessness and suicidality scores
obtained from the Suicide Behavior Questionnaire [28]. In a follow-up study examining psy-
chological pain as a pre-treatment risk indicator for suicidality and serious suicide attempts in
U.S. Veterans admitted to a suicide prevention program, findings showed that psychological
pain accounted for more shared variance with suicidality than assessments of depression,
hopelessness and impulsivity. In addition, we identified a subgroup of suicidal patients scoring
highest in psychological pain (24/57) by applying a previously tested screening score of
MBP�32 [defined as 0.5 SD above the mean of MDE patients [12]], which were predicted to
be at highest risk for negative treatment outcomes. At a 15-month follow-up, 9 of these 24
higher scoring patients experienced a documented serious suicidal event (as defined by criteria
on the C-SSRS) and 7/9 would have died if not found (One patient completed suicide). Taken
together, these results provided preliminary evidence that stratifying patients using psycholog-
ical pain scores could inform risk determination efforts in identifying patients at higher risk
for negative clinical outcomes and concentrated comorbid symptom acuity.
Psychological pain in substance use disorder
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In this study, we evaluated pretreatment assessments of psychological pain, depression,
anxiety and hopelessness in a substance addicted outpatient treatment population. We hypoth-
esized that psychological pain would correlate with ratings of co-administered symptom
assessments as we observed in previous findings from depressed, suicidal and healthy control
populations. In addition, we tested whether a subgroup of highest scoring SUD patients in
terms of pre-treatment psychological pain would be associated with greater severity of co-
assessed symptoms and elevated risk for poorer treatment outcomes (treatment retention
times and completion rates) relative to lower scoring patients.
Methods
Study design
A retrospective analysis of medical records was conducted for patients enrolled between
2011–2013 in the Substance Abuse Counseling Systems of The Gary Center (La Habra,
California (SACS); a community-based outpatient SUD treatment program. Data collected
included demographics, standardized clinical assessments and outcome variables including
completion/dropout status and length of stay (LOS). Patients were referred to the SACS pro-
gram by medical providers, regional non-profit centers, Orange County (OC) courts, legal
agencies and the OC Healthcare Agency. In addition, the SACS treatment program was
advertised on the internet (http://orange.networkofcare.org/mh/services/agency.aspx?pid=
TheGaryCenterSACS_348_2_0). The Institutional Review Board (IRB) of the County of
Orange Healthcare Agency approved the study and waived informed consent due to the mini-
mal risk associated with a retrospective chart review. We carefully protected the identity of the
patients by assigning each patient chart record a numerical code to ensure privacy. Research
personnel conducting chart reviews were blind to the study protocol.
Subjects
Medical records (N = 529) from January 2011 to December 2013 for male and female patients
�18 years of age and meeting the DSM-IV criteria for Substance Dependence or Substance
Abuse were screened for inclusion in the study. Patients with incomplete medical records or
who did not meet admission requirements were excluded from the study so that a total of 289
patient clinical charts were entered into the analyses. Successful program completion was
defined as fulfilling all required elements of the clinical protocol. Data collected in the retro-
spective chart review included demographics, program length of stay (LOS), completion status
and data from clinical rating scales. Detailed socioeconomic variables such as employment,
education and marital status were not available. All patients entering the program underwent
drug screening at admission and during the course of treatment for alcohol, tetrahydrocan-
nabinol (THC), methamphetamine, cocaine, opiates and benzodiazepines.
Exclusion criteria. Subjects under age 18 and those who had not agreed to each required
random drug screening as well as clinical assessment were excluded from the retrospective
analyses as were those chart records with missing assessment and/or data relevant to comple-
tion status.
Assessment
Data collected from the intake assessment upon admission included ratings from the Mee-
Bunney Psychological Pain Assessment Scale (MBP) [11, 12] the Beck Depression Inventory
(BDI)[29], the Beck Hopelessness Scale [30] and the Beck Anxiety Inventory (BAI) [31]. The
MBP is a ten-item instrument developed to rapidly assess current and recent psychological
Psychological pain in substance use disorder
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pain in general clinical populations. Broadly, scale items query the intensity of current and
recent pain, ask the respondent to separately consider psychological pain from any co-experi-
enced physical pain and address perceived tolerance to current or future psychological pain.
Examples of each category of item content include: “Circle the number that describes your
psychological pain at its worst intensity in the last 3 months”, “Compared to the worst physical
pain you can imagine, how would you rate your psychological pain at the present time?”, and
“How much more psychological pain do you think you can tolerate before it becomes unbear-
able?” Random drug testing conformed to the standards of the Department of Transportation
(DOT)-regulated biological fluid testing and included both observed urine and saliva
collection.
Program completion. Completion was task dependent and determined by successfully
completing the core programmatic components as designed by the SACS treatment team. Pri-
mary required elements included: attendance in the program >90 days, participation in 24
group sessions (16 process groups and 8 relapse prevention groups); four individual psycho-
therapy sessions, evidence of weekly attendance at community-based 12-step programs; two
psycho-educational classes; and six random, observed drug tests. In order to maximize the
opportunity to complete the treatment program and to accommodate relatively brief diver-
sions from treatment (i.e., court hearings and child visitation), there was no predetermined
maximum time for completion.
Program dropout. Non-completion status was defined as not completing the tasks neces-
sary for program completion (described above) and/or non-attendance for greater than 30
days.
Statistical methods
Various statistical analyses were performed with IBM SPSS software. The type I error rate was
set at .05 for all analyses. Chi-square analyses were conducted to study the association between
whether patients withdrew from treatment (i.e., dropout) and gender, and between dropout
and whether patients experienced high or low-to-moderate psychological pain (i.e., patients
dichotomized with respect to psychological pain). Between-group t-tests were conducted to
compare the differences between two groups with respect to continuous variables, such as test-
ing for a gender difference in Length of Stay (LOS). Pearson correlations were calculated to
determine the linear relationship between two continuous variables. A logistic regression was
conducted to examine the effect of psychological pain (high vs low-to-moderate) on dropout.
A Kaplan-Meier Survival (Retention) analysis was conducted to examine the effect of psycho-
logical pain (high vs low-to-moderate) on LOS, with the null hypothesis assuming that psycho-
logical pain had no impact on LOS.
Results
Demographics
Data from 289 patients (212 males and 77 females) were included in the analyses (Table 1 and
S1 File). Patients self-identifying as Hispanic comprised a slight majority of the population
(55%). Methamphetamine was the most frequently reported substance used (Polysubstance
and as drug of choice) (82.4%) followed by alcohol (64.7%) and cannabis (56.4%). The major-
ity of patients were polysubstance users (n = 228; 78.9%), while 21.1% (n = 61) reported using
a single drug of choice. The combined number of drugs used by patients ranged from two
(n = 116; 40.1%) to five (n = 10; 3.5%) with the majority using two substances, methamphet-
amine and alcohol.
Psychological pain in substance use disorder
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Clinical ratings
As described in Table 2 scoring of clinical assessments for all patients indicated low levels of
depression (BDI), anxiety (BAI) and hopelessness (BHS). Psychological pain scores were in the
Table 2. Mean scores for Mee-Bunney Psychological Pain Assessment Scale (MBP), Beck Depression Inventory
(BDI), Beck Anxiety Inventory (BAI) and Beck Hopelessness Scale (BHS).
Scale Score (±SD) Scoring Category
MBP 23.57 (8.87) Low-moderate
BAI 11.98 (14.46) Mild
BHS 4.8 (4.48) Mild
BDI 8.54 (6.60) Minimal
https://doi.org/10.1371/journal.pone.0216266.t002
Table 1. Demographic and substance use characteristics.
Gender /mean age ± SD N Percent (%)
Males (32.8yrs± 10.9) 212 73.4
Females (34.7yrs ± 10.1) 77 26.6
Combined (33.5yrs ±10.7) 289 100.0
Ethnicity N Percent (%)
Caucasian 100 34.6
Hispanic 159 55.0
Black 12 4.2
Asian 7 2.4
Pacific Islander 2 0.7
Other 9 3.1
Drug of choice with (+) or without (-) polysubstance
Alcohol 205 70.9
(+) 187 91.2
(-) 18 .09
Tetrahydrocannabinol (THC) 178 61.6
(+) 163 91.6
(-) 15 8.4
Methamphetamine 238 82.4
(+) 213 89.4
(-) 25 11
Cocaine 68 23.5
(+) 66 97.1
(-) 2 2.9
Opiates 51 17.6
(+) 0 17.6
(-) 51 0
Benzodiazepines 8 2.8
(+) 7 87.5
- drug 1 12.5
Number of drugs used
One 61 21.1
Two 116 40.1
Three 64 22.1
Four 38 13.2
Five 10 3.5
https://doi.org/10.1371/journal.pone.0216266.t001
Psychological pain in substance use disorder
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low-moderate range based on previous studies in normal and depressed populations (Mee,
et al., 2011). The estimates of Cronbach’s alpha indicated high internal reliability for all assess-
ment instruments: MBP = .902, BDI = .941, BHS = .876, BAI = .958.
The correlations among the clinical assessments are described in Table 3. The strongest
relationship was between psychological pain (MBP) and depression (BDI), and the relation-
ship was positive.
Completion of treatment and Length of Stay (LOS). Program completion was defined
as satisfying all clinical requirements of the SACS program. Dropouts participated in the pro-
gram but failed to complete.
Completion rates. 68 patients (23.5%) completed the treatment program, whereas 221
(76.5%) did not. Significantly fewer patients with higher MBP scores completed the treatment
(11.3%) than patients with lower scores did (26.3%). The association between dropout rate and
gender was statistically significant, with the dropout rate being higher for males (82.1%) than
for females (61.0%), Χ2 = 12.75, df = 1, p< .001.
Treatment retention/Length of Stay (LOS). The mean number of days in treatment for
all patients (completers and dropouts) was 117.1 days (SD = _79.4; range from 7 to 397 days;
median number of days spent in treatment was 98 days).
Gender. The difference in LOS between female (M = 127.9 days, SD = 83.4) and male
(M = 111.2 days, SD = 76.7 days) patients was not statistically significant, t(287) = 1.71, p = .09.
Completion status. Completers stayed in treatment for an average of 197.4 days com-
pared to 92.3 days for dropouts, and the difference was statistically significant, t(287) = 11.52,
p< .001. The earliest a patient completed the treatment was in 94 days, whereas the longest a
patient required was more than a year (397 days).
Psychological pain (MBP) ratings: Completers vs Dropouts. Although overall MBP
scores were in the low moderate range for the total patient population (Table 2), patients who
dropped out (M = 24.4, SD = 9.09) were statistically significantly higher on psychological pain
than completers were (M= 20.9, SD = 7.59), t(287) = -2.82, p = .005. MBP scores were also sig-
nificantly higher for dropouts with briefer length of stays (LOS < 65 days) than for dropouts
with longer LOS (mean MBP <65LOS = 25.9; mean MBP >65 LOS = 22.33; t(219) = 3.34, p<
.001).
Correlation between length of stay (LOS) and ratings for psychological pain (MBP)
depression (BDI), anxiety (BAI) and hopelessness (BHS). LOS was negatively correlated
with psychological pain (MBP), depression (BDI), and anxiety (BAI), with the correlations
being statistically significant (see Table 3 for the Pearson correlations). LOS was most notably
Table 3. Correlations among the Mee-Bunney Psychological Pain Assessment Scale (MBP), Beck Depression
Inventory (BDI), Beck Hopelessness Scale (BHS), Beck Anxiety Inventory (BAI) and treatment program Length
of Stay (LOS).
LOS MBP BDI BHS BAI
LOS 1.00
MBP −.20��� 1.00
BDI −.17�� .77��� 1.00
BHS −.11 .63��� .64��� 1.00
BAI −.14� .61��� .62��� .44��� 1.00
� p< .05
��p< .01
���p� .001
https://doi.org/10.1371/journal.pone.0216266.t003
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negatively correlated with MBP (r = –.20, p = .001), then with BDI (r = –.17, p = .005) and with
BAI (r = –.14, p = .022). LOS was not correlated with hopelessness (BHS; r = -.107, p = .07).
Severity category of psychological pain (MBP) and clinical outcomes. Fifty-three
patients (18.3%) met the criterion for high psychological pain—the threshold to consider
patients as experiencing high psychological pain (MBP�32) was established in 2011 and
shown to be applicable in two separate clinical populations of 72 and 57 patients (9,10). As
illustrated in Table 4, patients experiencing high levels of psychological pain (MBP) at intake
also scored statistically significantly higher in depression (BDI), anxiety (BAI) and hopeless-
ness (BHS) compared to patients scoring low-moderate on psychological pain assessment.
Table 5 illustrates significant differences in clinical outcomes between patients scoring
above and below-threshold for high psychological pain (MBP)
Completion rates and LOS. A logistic regression analysis was conducted to determine
the effect of the dichotomized pre-treatment MBP scores (i.e., high vs. low) on treatment drop-
out. The results showed that patients scoring high on MBP pre-treatment were more likely to
dropout of treatment than patients scoring low on MBP pre-treatment were to, χ2 (2) = 5.02,
p = .025, odds ratio 2.79, relative risk = 1.21. Regarding treatment retention times, patients
scoring higher on psychological pain pre-treatment (M = 90 days) had a lower LOS than
patients scoring lower on psychological pain did (M = 123 days), and the trend was statistically
significant, t (287) = 2.75, p = .006. In addition, for only the patients who dropped out of treat-
ment, LOS was statistically significantly shorter for those with high psychological pain (M =
73.1 days) than for patients with lower psychological pain (M = 97.5 days), t(219) = 2.31, p =
.02. Although patients high in psychological pain exhibited diminished LOS and lower subse-
quent completion rates, robust increases in both of these variables for patients who remained
in treatment for more than 100 days were observed. Specifically, when LOS was greater than
100 days, completion rates for the patients high in psychological pain increased from 11.3% to
35.3% and the low-moderate pain group increased from 26.3% to 48.3%. Overall, 96.8% of all
completions for both groups occurred after 100 days of treatment.
Retention curves and survival analyses. Kaplan-Meier survival analyses and retention
curves were estimated to further compare the high (n = 53) and low-to-moderate (n = 236)
psychological pain subgroups and to provide a visualization of LOS and dropout patterns.
These analyses revealed significant differences between the patient curves (Log Rank
Table 4. Significant differences in clinical assessment symptom severity between subgroups of patients scoring above and below threshold for high psychological
pain (MBP).
Rating Scale MBP <32 (Low-Moderate)
n = 236
MBP�32 (High)
n = 53
t-test p-value
BDI 6.44 (Minimal) 17.77 (Mild) df 278, t = -14.99 p < .001
BAI 8.24 (Minimal) 28.75 (Moderate) df 278, t = -8.33 p < .001
BHS 3.53 (Minimal) 10.31 (Moderate) df 253, t = -11.73 p < .001
https://doi.org/10.1371/journal.pone.0216266.t004
Table 5. Significantly fewer high scoring patients on pretreatment psychological pain assessment (MBP� 32)
completed treatment than lower scoring patients.
Outcome measure MBP�32 (high)
N = 53
MBP <32 (lower)
N = 236
p-value
Completers
N = 68
6 62 p < .02, df 1, χ2 = 5.38
Dropouts
N = 221
47 174 p = .02, df 1, χ2 = 5.38
https://doi.org/10.1371/journal.pone.0216266.t005
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p = 0.001) in terms of retention rates and patterns (Fig 1). Even at similar time points, over-
representation of completions clustering on the Low-moderate pain curve while largely absent
on the High pain curve is visually apparent. A separate analysis performed on the dropout
group alone comparing the high and low-to-moderate psychological pain groups reflected a
similar difference between the curves (p = .011). Sixty-six percent (n = 35) of high scoring
MBP patients had dropped out before the first patient completed the treatment program (day
94), and by day 129, 75% of high-category psychological pain patients had dropped out.
Patients high on psychological pain reached 50% attrition after just 53 days compared to 108
days for patients lower on psychological pain.
Program retention curves for High and Low-moderate pain categories. Log Rank analysis
showed that the curves significantly differed between the high pain and low-moderate pain
patient groups (χ2 = 11.1, p = .001). (+) indicates individual patient-program completion
event. There is a notable clustering of patient completions on the low-moderate pain curve
while relatively absent on the high pain curve at similar time points.
Fig 1. Treatment retention (Kaplan-Meier survival) curves illustrated for SUD patients categorized as High or Low-moderate by psychological pain assessment at
program admission.
https://doi.org/10.1371/journal.pone.0216266.g001
Psychological pain in substance use disorder
PLOS ONE | https://doi.org/10.1371/journal.pone.0216266 November 7, 2019 9 / 13
Discussion
This study is, to our knowledge, the first to specifically focus on characterizing psychological
pain in a population seeking treatment for substance use disorders. Primarily, the data from
this effort add to a growing body of evidence that psychological pain is a quantifiable construct
in patients suffering from SUD. This study provides preliminary evidence of higher pre-treat-
ment psychological pain measured at intake within eventual program dropouts compared to
patients who completed treatment. We believe this modest difference in mean psychological
pain scores is primarily of research value, which, if replicated in larger populations supports a
role for psychological pain in SUD. Additionally, we found evidence that elevated pretreat-
ment psychological pain is associated with negative treatment outcomes such as diminished
treatment retention time (LOS) and reduced likelihood for program completion. We chose
program completion as a proximal indicator of overall treatment outcome as follow-up data
for maintain abstinence were not available.
Dropout was the most frequent treatment outcome for the SACS patients. This observation
agrees with data from the Treatment Episode Data Set (TEDS) published by SAMHSA [32].
Our patient population exhibited dropout rates somewhat higher than some programs reported
to the TEDS nationwide, however, dropout rates greater than 50% have been reported from
long term outpatient community-based treatment programs (Levin et al, 27). We did find that
completion rates in the SACS population nearly doubled when patients remained in treatment
at least 100 days, reaching levels in agreement with data from the TEDS Government analysis.
Pre-treatment levels of anxiety, depression and hopelessness for the total treatment popula-
tion indicated minimal comorbid psychopathology. A simple binary risk stratification method
based on psychological pain (MBP scores), previously developed and applied to depressed and
suicidal psychiatric populations [11, 12] re-grouped patient data into high and low-moderate cate-
gories of pain. The ‘high’ pain category group, relative to the lower pain group, exhibited signifi-
cantly greater dropout rates, had more severe psychopathology (depression and anxiety) scores as
well as a pronounced reduction in LOS. Survival curve analyses confirmed differences in comple-
tion patterns and LOS which suggest that our high and low-moderate pain risk categorization
scoring method separated patients into two sub-populations differing in treatment outcomes.
Incorporating systematic psychological pain screening within current standard intake assessment
paradigms, may aid in identifying patients at program entry posing elevated risk for early dropout
and offer the potential for outcome modifying interventions such as increasing retention time.
Each of the relatively few high-pain category patients who successfully completed the treatment
protocol (only 2.1% of the total patient sample) were associated with LOS>129 days; nearly twice
the mean LOS for the total high pain population. In contrast, 89% of high pain patients who
dropped out of treatment, did so before the first 102 days of treatment.
There are a number of limitations to this modestly sized, retrospective observational study.
Caution is warranted in generalizing our results pending replication in larger populations.
Future studies would benefit from a prospective design, however, retrospective designs can be
appropriately used in the context of multiple outcome measures [33]. Chart data from patients
who were non-compliant with program-administered random drug testing or who did not
complete the clinical assessments were excluded from the final analyses. This could have intro-
duced bias to the sample in terms of motivation to participate in treatment, maintain sobriety
or otherwise impact outcomes measures. Important psychosocial demographic and socioeco-
nomic factors, including employment, marital and educational status or assessment data on
addiction severity were not available for inclusion in data analysis due to limitations on what
was collected by the SACS clinical treatment protocol. A similar impact on study implications
resulted from the limited detail available on substance use history patterns imposed by the
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naturalistic post-clinical study design. An additional limitation involves the determination of
the threshold for separating the highest scoring patients from lower scoring patients in terms
of psychological pain (MBP� 32) to inform risk for negative clinical outcomes a priori. This
scoring threshold derived from the initial validation study of the MBP (10) where a determina-
tion was made by clinical observation and inspection of co-administered scale rating patterns.
The threshold was found to be informative in a follow-up study (11) and those collective
results informed the decision to apply it to the present population. A goal of this study was to
examine the clinical usefulness of our previously tested threshold score of MBP� 32 as a pre-
treatment indicator for elevated risk of poorer clinical outcomes (and more intense comorbid
psychopathology) relative to lower scoring patients. While these findings support the informa-
tiveness of that threshold in a third clinical population, they are currently of primarily clinical
interest and value. Absent a complete item validity analysis in a larger population sample,
including a confirmatory factor analysis, the validity of the MBP for assessing psychological
pain in SUD and the nature of the role of psychological pain in SUD awaits further clarifica-
tion. An additional limitation involves the likely collinearity between variables included in the
regression analyses. Only one predictor could be included in our logistic regression model
when the factors that influenced patients dropping out of treatment were investigated. This
was because the other predictors (e.g., depression) were moderately correlated with psycholog-
ical pain (MBP) and thus, the sample size of the study could not offset the correlations between
the predictors. Understanding the relationship between psychological pain and treatment
dropout is at an early stage and many of the analyses were conducted without controlling for
various predictors. A future study with larger samples could incorporate what has been learned
to control for other factors. A prior study, however, suggested that the MBP explains additional
variance to that contributed by hopelessness and depression (10).
Conclusion
In this study, we present evidence that elevated pre-treatment psychological pain may nega-
tively impact program completion and LOS in outpatient substance treatment. The highest
scoring patients on psychological pain assessment were ultimately 1.21 times more likely to
drop out and to participate in treatment significantly fewer days compared with lower pain
scoring peers. Whether this reduction in completion rates is a direct or indirect consequence
of decreased LOS remains unanswered and further work in larger populations is needed to
better understand these relationships. The survival curve analysis demonstrated a preferential
clustering of completions on the lower pain group curve and relative lack of completions on
the higher pain curve at identical time points. This suggests that a factor involving high psy-
chological pain, apart from reduced LOS, may also negatively influence completion likelihood.
Regardless, the study of psychological pain represents a novel area to further our understand-
ing of the unpredictable outcomes in substance use disorders treatment. The subset of patients
experiencing very high levels of psychological pain at treatment initiation may be inherently
poorer candidates for outpatient substance treatment and early identification could allow for
prompt referral to accessing higher levels of care. Efforts to further our understanding on the
negative influence of high pre-treatment levels of psychological pain on completion rates and
LOS offer additional opportunities for improving substance treatment outcomes.
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